132 related articles for article (PubMed ID: 34031538)
1. Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas.
Gondo N; Sakai Y; Zhang Z; Hato Y; Kuzushima K; Phimsen S; Kawashima Y; Kuroda M; Suzuki M; Okada S; Iwata H; Toyama T; Rezano A; Kuwahara K
Lab Invest; 2021 Aug; 101(8):1048-1059. PubMed ID: 34031538
[TBL] [Abstract][Full Text] [Related]
2. Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival.
Rezano A; Kuwahara K; Yamamoto-Ibusuki M; Kitabatake M; Moolthiya P; Phimsen S; Suda T; Tone S; Yamamoto Y; Iwase H; Sakaguchi N
BMC Cancer; 2013 Dec; 13():562. PubMed ID: 24289229
[TBL] [Abstract][Full Text] [Related]
3. BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2.
Bhatia V; Barroso SI; García-Rubio ML; Tumini E; Herrera-Moyano E; Aguilera A
Nature; 2014 Jul; 511(7509):362-5. PubMed ID: 24896180
[TBL] [Abstract][Full Text] [Related]
4. DSS1 is required for the stability of BRCA2.
Li J; Zou C; Bai Y; Wazer DE; Band V; Gao Q
Oncogene; 2006 Feb; 25(8):1186-94. PubMed ID: 16205630
[TBL] [Abstract][Full Text] [Related]
5. DSS1 allosterically regulates the conformation of the tower domain of BRCA2 that has dsDNA binding specificity for homologous recombination.
Alagar S; Bahadur RP
Int J Biol Macromol; 2020 Dec; 165(Pt A):918-929. PubMed ID: 33011260
[TBL] [Abstract][Full Text] [Related]
6. Promotion of BRCA2-Dependent Homologous Recombination by DSS1 via RPA Targeting and DNA Mimicry.
Zhao W; Vaithiyalingam S; San Filippo J; Maranon DG; Jimenez-Sainz J; Fontenay GV; Kwon Y; Leung SG; Lu L; Jensen RB; Chazin WJ; Wiese C; Sung P
Mol Cell; 2015 Jul; 59(2):176-87. PubMed ID: 26145171
[TBL] [Abstract][Full Text] [Related]
7. The proteasome is involved in determining differential utilization of double-strand break repair pathways.
Gudmundsdottir K; Lord CJ; Ashworth A
Oncogene; 2007 Nov; 26(54):7601-6. PubMed ID: 17563742
[TBL] [Abstract][Full Text] [Related]
8. Conformational stability of PCID2 upon DSS1 binding with molecular dynamics simulation.
Liu Q; Hu G; Cao Z; Wang J; Chen H
J Mol Model; 2015 May; 21(5):127. PubMed ID: 25914122
[TBL] [Abstract][Full Text] [Related]
9. Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals.
Marston NJ; Richards WJ; Hughes D; Bertwistle D; Marshall CJ; Ashworth A
Mol Cell Biol; 1999 Jul; 19(7):4633-42. PubMed ID: 10373512
[TBL] [Abstract][Full Text] [Related]
10. Depletion of DSS1 protein disables homologous recombinational repair in human cells.
Kristensen CN; Bystol KM; Li B; Serrano L; Brenneman MA
Mutat Res; 2010 Dec; 694(1-2):60-4. PubMed ID: 20817001
[TBL] [Abstract][Full Text] [Related]
11. Human TREX2 components PCID2 and centrin 2, but not ENY2, have distinct functions in protein export and co-localize to the centrosome.
Cunningham CN; Schmidt CA; Schramm NJ; Gaylord MR; Resendes KK
Exp Cell Res; 2014 Jan; 320(2):209-18. PubMed ID: 24291146
[TBL] [Abstract][Full Text] [Related]
12. Cancer-causing BRCA2 missense mutations disrupt an intracellular protein assembly mechanism to disable genome maintenance.
Lee M; Shorthouse D; Mahen R; Hall BA; Venkitaraman AR
Nucleic Acids Res; 2021 Jun; 49(10):5588-5604. PubMed ID: 33978741
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
14. Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.
Xu H; Yan M; Patra J; Natrajan R; Yan Y; Swagemakers S; Tomaszewski JM; Verschoor S; Millar EK; van der Spek P; Reis-Filho JS; Ramsay RG; O'Toole SA; McNeil CM; Sutherland RL; McKay MJ; Fox SB
Breast Cancer Res; 2011 Jan; 13(1):R9. PubMed ID: 21255398
[TBL] [Abstract][Full Text] [Related]
15. DSS1 and ssDNA regulate oligomerization of BRCA2.
Le HP; Ma X; Vaquero J; Brinkmeyer M; Guo F; Heyer WD; Liu J
Nucleic Acids Res; 2020 Aug; 48(14):7818-7833. PubMed ID: 32609828
[TBL] [Abstract][Full Text] [Related]
16. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells.
Gudmundsdottir K; Lord CJ; Witt E; Tutt AN; Ashworth A
EMBO Rep; 2004 Oct; 5(10):989-93. PubMed ID: 15359272
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
Takada M; Nagai S; Haruta M; Sugino RP; Tozuka K; Takei H; Ohkubo F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Sato Y; Ogawa S; Kaneko Y
Genes Chromosomes Cancer; 2017 May; 56(5):405-420. PubMed ID: 28124401
[TBL] [Abstract][Full Text] [Related]
18. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
20. Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains.
Siaud N; Barbera MA; Egashira A; Lam I; Christ N; Schlacher K; Xia B; Jasin M
PLoS Genet; 2011 Dec; 7(12):e1002409. PubMed ID: 22194698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
